
ENDRA Life Sciences NDRA
$ 3.46
-0.57%
Quarterly report 2025-Q3
added 11-14-2025
ENDRA Life Sciences Total Current Liabilities 2011-2026 | NDRA
Annual Total Current Liabilities ENDRA Life Sciences
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 605 K | 903 K | 1.7 M | 1.54 M | 987 K | 2.07 M | 975 K | 848 K | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.07 M | 605 K | 1.2 M |
Total Current Liabilities of other stocks in the Diagnostics research industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Biomerica
BMRA
|
1.74 M | $ 2.16 | 1.41 % | $ 4.96 M | ||
|
Bioventus
BVS
|
160 M | $ 9.15 | 1.67 % | $ 610 M | ||
|
Biodesix
BDSX
|
14.3 M | $ 15.54 | 5.79 % | $ 2.02 B | ||
|
Fulgent Genetics
FLGT
|
72.9 M | $ 16.34 | 0.06 % | $ 494 M | ||
|
Guardant Health
GH
|
303 M | $ 83.59 | -1.54 % | $ 10.5 B | ||
|
ICON Public Limited Company
ICLR
|
2.8 B | $ 101.28 | 0.93 % | $ 8.35 B | ||
|
IDEXX Laboratories
IDXX
|
1.15 B | $ 570.21 | -1.43 % | $ 45.9 B | ||
|
Akumin
AKU
|
169 M | - | -17.87 % | $ 25.9 M | ||
|
Lantheus Holdings
LNTH
|
333 M | $ 74.24 | -1.97 % | $ 5.01 B | ||
|
Enzo Biochem
ENZ
|
24.8 M | - | -8.98 % | $ 14.8 K | ||
|
Medpace Holdings
MEDP
|
1.34 B | $ 460.74 | 0.83 % | $ 13.3 B | ||
|
Check-Cap Ltd.
CHEK
|
1.81 M | - | - | $ 9.42 M | ||
|
Myriad Genetics
MYGN
|
134 M | $ 4.61 | -1.07 % | $ 427 M | ||
|
National Research Corporation
NRC
|
36.6 M | $ 17.44 | -0.4 % | $ 390 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
13.8 M | - | - | $ 562 M | ||
|
Pacific Biosciences of California
PACB
|
72.8 M | $ 1.39 | - | $ 417 M | ||
|
DermTech
DMTK
|
13.4 M | - | -11.32 % | $ 2.94 M | ||
|
Aspira Women's Health
AWH
|
5.78 M | - | -6.19 % | $ 10.5 M | ||
|
Personalis
PSNL
|
31.1 M | $ 7.78 | 2.23 % | $ 461 M | ||
|
Co-Diagnostics
CODX
|
5.75 M | $ 4.4 | 101.83 % | $ 129 M | ||
|
RadNet
RDNT
|
587 M | $ 59.87 | -3.03 % | $ 4.5 B | ||
|
Accelerate Diagnostics
AXDX
|
66.6 M | - | -61.36 % | $ 2.46 M | ||
|
Global Cord Blood Corporation
CO
|
647 M | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
54.2 M | - | 1.08 % | $ 308 M | ||
|
Senseonics Holdings
SENS
|
24.3 M | $ 6.66 | 0.6 % | $ 278 M | ||
|
Sotera Health Company
SHC
|
250 M | $ 13.84 | -0.32 % | $ 3.93 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
1.27 B | - | - | $ 10.7 B | ||
|
Soleno Therapeutics
SLNO
|
61.4 M | $ 31.34 | -1.2 % | $ 1.59 B | ||
|
Charles River Laboratories International
CRL
|
1.12 B | $ 159.19 | 0.75 % | $ 7.89 B | ||
|
IQVIA Holdings
IQV
|
8.34 B | $ 166.09 | -0.52 % | $ 28.6 B | ||
|
Neuronetics
STIM
|
30.5 M | $ 1.46 | -9.06 % | $ 96.3 M | ||
|
Biocept
BIOC
|
5.51 M | - | -13.05 % | $ 7.29 M | ||
|
Invitae Corporation
NVTA
|
108 M | - | - | $ 21.2 M | ||
|
BioNano Genomics
BNGO
|
22.9 M | $ 1.18 | -19.18 % | $ 6.43 M | ||
|
Mettler-Toledo International
MTD
|
1.2 B | $ 1 264.46 | 2.05 % | $ 26.1 B | ||
|
Interpace Biosciences
IDXG
|
10.6 M | $ 1.71 | 0.73 % | $ 7.5 M | ||
|
Illumina
ILMN
|
1.55 B | $ 125.98 | 1.77 % | $ 20 B | ||
|
Twist Bioscience Corporation
TWST
|
91.4 M | $ 47.49 | 6.72 % | $ 2.84 B | ||
|
QIAGEN N.V.
QGEN
|
544 M | - | - | $ 10.6 B | ||
|
Precipio
PRPO
|
3.14 M | $ 26.6 | -1.23 % | $ 34.5 M | ||
|
Celcuity
CELC
|
31.7 M | $ 102.01 | -4.44 % | $ 4.02 B | ||
|
Chembio Diagnostics
CEMI
|
39.3 M | - | 0.22 % | $ 16.8 M | ||
|
Laboratory Corporation of America Holdings
LH
|
2.82 B | $ 266.12 | 0.64 % | $ 22.1 B | ||
|
Motus GI Holdings
MOTS
|
3.27 M | - | -34.28 % | $ 263 K | ||
|
NeoGenomics
NEO
|
88.3 M | $ 7.86 | -2.96 % | $ 1.01 B | ||
|
Natera
NTRA
|
310 M | $ 194.52 | -2.78 % | $ 19.1 B |